cvcv - PowerPoint PPT Presentation

About This Presentation
Title:

cvcv

Description:

Welcome to the amoebiasis e-learning module. Amoebiasis is a parasitic ... A refractile wall containing chitin, allows the cyst to survive stomach acid. ... – PowerPoint PPT presentation

Number of Views:249
Avg rating:3.0/5.0
Slides: 26
Provided by: matthew386
Learn more at: https://isp.swanih.org
Category:

less

Transcript and Presenter's Notes

Title: cvcv


1
cvcv
cvcv
cvcv
cvcv
cvcv
Clinical
Summary
Introduction
Epidemiology
Disease biology
Amoebiasis
E-Learning Module
Click here to begin
Matt Pugh
2
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Introduction Welcome to the amoebiasis
e-learning module. Amoebiasis is a parasitic
protozoan disease that affects the gut mucosa and
liver, resulting in dysentery, colitis and liver
abscess. The causative agent, Entamoeba
histolytica, is a potent pathogen that is spread
via ingestion of contaminated food and water.
Globally, amoebiasis is highly prevalent, and is
the second leading cause of death to parasitic
disease. This resource will outline the disease
biology, epidemiology and clinical principles of
amoebiasis.
3
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
  • Learning Outcomes
  • The learning outcomes for this moudule are
  • Understand the biology, life cycle and mode of
    transmission of the amoebiasis causative
    organism, Entamoeba histolytica.
  • Understand the pathological processes that lead
    to disease in amoebiasis
  • Know the distribution of amoebiasis worldwide,
    and which geographical, cultural and economic
    factors can pre-dispose to the disease
  • Know how the disease presents according to the
    infected organ system.
  • Be able to outline the treatment and management
    of symtomatic and asymtomatic patients.
  • Outline the key features of the developing
    gal-lectin vaccine.

4
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
How to use this module The module is split into
five main sections introduction, disease
biology, epidemiology, clinical and summary. The
information required to complete the learning
outcomes are contained within the disease
biology, epidemiology and clinical sections. At
the end of each of these sections there will be a
self assessment section. You will require a pen
and paper to write down your answers. How to
navigate
Navigate through the module using the blue arrows
to go back and forth. You may skip straight to,
or back to a section by clicking the tabs at the
top of screen. Additionally, you may skip through
the sub-sections by clicking on the tabs at the
side of the screen.
5
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Causative Organism
  • The causitive orgainism is parasitic protazoan,
    called Entamoeba histolytica.
  • What was once thought to be a single entity, is
    now recognised as two morphologically identical
    but genetically distinct forms E. histolytica
    (pathogen) and E. dispar (commensal).
  • This has affected our understanding of amoeba
    distribution. Many suspected cases of E.
    histolytica carrier, may simply have been E.
    dispar colonisation
  • The WHO recommendes that E. histolytica
    colonisation should be treated, however,
    treatment is unnecessary for E. dispar
    colonisation

Causative Organism
Life Cycle and transmission 1
Life Cycle and transmission 2
Pathogenesis 1
Pathogenesis 2
Self Assessment
E. Histolytica
6
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Life cycle and transmission 1
  • Entammoeba histolytica has a biphasic life
    cycle, existing in two forms as an infectious
    cyst and an amoeboid trophozoite

Causative Organism
Life Cycle and transmission 1
Life Cycle and transmission 2
Pathogenesis 1
Pathogenesis 2
Self Assessment
7
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Life cycle and transmission 2
  • Cysts (10-15µm) are ingested via contaminated
    food or water. A refractile wall containing
    chitin, allows the cyst to survive stomach acid.
  • In the terminal ileum or colon, the parasite
    excysts and begins the trophozoite stage.
  • Trophozoites (10-50µm) are highly motile and
    pleomorphic. They are unable to survive outside
    the human gut.
  • Energy is derived from the ingestion of bacteria
    and food particles. No mitochondria are present
    in trophozoites. Respiration enzymes are
    prokaryotic in origin and are anaerobic,
    converting
  • glucose pyruvate
    ethanol
  • Trophozoites reproduce by binary fission and
    encyst in the colonic wall. Cysts are passed in
    the stool where they become infectious.
  • The signal for encystation is thought to be via
    epithelial galactose/N-acetylgalactosamine
    specific lectin (gal-lectin) binding protein.

Causative Organism
Life Cycle and transmission 1
Life Cycle and transmission 2
Pathogenesis 1
Pathogenesis 2
Self Assessment
8
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Pathogenesis 1
  • Amoebic trophozoites invade the colon causing
    colitis. They may also invade the portal
    circulation and travel to the liver, causing
    liver abscess.
  • Gastrointestinal Pathology
  • The spectrum of colitis in amoebiasis ranges
    from mucosal thickening, to multiple cyst
    formation, to diffuse Inflammation / oedema, to
    necrosis and perforation of colonic wall.
  • Binding of E. histolytica to epithelial cells via
    gal-lectin. This molecule shows homologous to
    human CD59, conferring resistance to complement .
    A change in the epithelial permeability is
    induced, probably via the inter-cellular tight
    junctions.
  • Cell lysis and apoptosis of mucosa are thought
    to be mediated by amoebapores, peptides capable
    of forming pores in lipid bi-layers.
  • Trophozoites invade through to the submucosa
    causing flask shaped cysts .
  • Cysteine proteases released by trophozoites
    digest extracellular matrix in liver and colon,
    and induce interleukin-1 mediated inflammation.
    Proteases also cleave IgA and IgG antibodies.
  • Neutrophils and macrophages are drawn to invasion
    sites. E. histolytica can lyse neutrophils
    leading to further tissue damage, and
    contributing towards the induction of diarrhoea.
  • Inflammation is a significant cause of tissue
    damage, however, innate immunity may be the main
    combatant against the disease.

Causative Organism
Life Cycle and transmission 1
Life Cycle and transmission 2
Pathogenesis 1
Pathogenesis 2
Self Assessment
9
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Pathogenesis 2
  • Hepatic Pathology
  • Trophozoites invading the colonic mucosa may
    enter the hepatic circulation and reach the liver

Causative Organism
  • Well circumscribed abscesses are formed in the
    liver containing liquefied cells surrounded by
    inflammatory cells and trophozoites
  • Adjacent parenchyma is usually unaffected

Life Cycle and transmission 1
Life Cycle and transmission 2
Amoebic liver abscess
Pathogenesis 1
Pathogenesis 2
Self Assessment
Histological cross section of classical flask
shaped amoebic ulcer in colonic mucosa.
Amoebic colitis with multiple ulcer formation
10
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Questions
  • 1) Which of the following organisms is the
    pathogenic causitive agent of amoebiasis, and
    which is a commensal?
  • Entamoeba histolytica .
  • Entamoeba dispar .
  • Draw a simple diagram oulining the life cycle of
    entamoeba histolytica.
  • Which two organs does E. histolytica primarily
    invade?
  • What is the name and mechanism of action of the
    peptide responsible for cell lysis and apoptosis
    in the mucosa?
  • What is the name of the enzyme group released by
    trophozoites to digest the extra-cellular matrix

Causative Organism
Life Cycle and transmission 1
Life Cycle and transmission 2
Pathogenesis 1
Pathogenesis 2
Self Assessment
Reveal Answers
11
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Answers
  • 1) Which of the following organisms is the
    pathogenic causitive agent of amoebiasis, and
    which is a commensal?
  • Entamoeba histolytica Pathogen.
  • Entamoeba dispar Commensal.
  • Draw a simple diagram oulining the life cycle of
    entamoeba histolytica.
  • 3) Which two organs does E. histolytica
    primarily invade?
  • Colon and liver
  • 4) What is the name and mechanism of action of
    the peptide responsible for cell lysis and
    apoptosis in the mucosa?
  • Cell lysis and apoptosis of mucosa are
    thought to be mediated by amoebapores, These
    peptides form pores in lipid bi-layers of mucosal
    cells, leading to cell leakage resulting in lysis
    and apoptosis.
  • 5) What is the name of the enzyme group
    released by trophozoites to digest the
    extra-cellular matrix ?
  • Cysteine proteases

Causative Organism
Life Cycle and transmission 1
Life Cycle and transmission 2
Pathogenesis 1
Pathogenesis 2
Self Assessment
12
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Epidemiology
  • Amoebiasis is found primarily in developing
    tropical and subtropical countries where
    sanitation is poor, leading to a direct link
    between faeces and ingestion (see Box-1).
    Occasionally cases are reported in non-endemic
    areas e.g. UK and USA. Usually due to travel and
    immigration from endemic areas.
  • There are an estimated 40,000-100,000 deaths due
    to amoebiasis worldwide each year.

Epidemiology
Susceptibility
Self Assessment
Box-1. Amoebiasis rates/figures in endemic
regions -Egypt accounts for 38 of patients
presenting with acute diarrhoea in outpatient
clinic. -Mexico1.3 million cases reported in
1996. -Hue, Vietnam 1500 of a 1million
population over 5 years
13
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Susceptibility
  • Generally considered to affect children and
    adults, of both sexes equally. However, some data
    and anecdotal evidence suggests a male
    predominance.
  • Amoebic liver abscesses are most common in males,
    18-55.
  • Susceptibility to liver abscess conferred by
    HLA-DR3 and complotype SC01 in the Mexican
    populations
  • Other risk factors include oral and anal sex, and
    contact with contaminated enema apparatus.

Epidemiology
Susceptibility
Self assessment
14
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Questions
  • How many deaths are caused by amoebiasis each
    year?
  • 1000 5000 b) 40,000-100,000 c)
    500,000-1,000,000
  • Which part of the world is amoebiasis primarily
    found?
  • Developed countries b) Tropical and subtropical
    c)Cold climates
  • Does amoebiasis affect males or females more?
  • Apart from poor sanitation, what other risk
    factor pre-dispose to amoebiasis infection?

Epidemiology
Susceptibility
Self assessment
Reveal Answers
15
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Answer
  • How many deaths are caused by amoebiasis each
    year?
  • 1000 5000 b) 40,000-100,000 c)
    500,000-1,000,000
  • Which part of the world is amoebiasis primarily
    found?
  • Developed countries b) Tropical and subtropical
    c)Cold climates
  • Does amoebiasis affect males or females more?
  • Thought to affect both sexes equally,
    however, anecdotal evidence suggests a male
    predominance.
  • 4) Apart from poor sanitation, what other risk
    factor pre-dispose to amoebiasis infection?
  • Other risk factors include oral and anal
    sex, and contact with contaminated enema
    apparatus.

Epidemiology
Susceptibility
Self assessment
16
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Presentation
  • Some individuals carry E. histolytica
    asymptomatically. 4 -10 will go on to develop
    the disease within a year.
  • Gastroenterological
  • Gradual onset (weeks) of bloody diarrhoea,
    occasionally with small volumes of mucoid stool.
    If blood is not visible, stool is usually haem
    positive due to the breach of the mucosa.
  • Abdominal pain and tenderness.
  • Leucocytes and pus may be present in stool.
    Fever present in lt40 of patients.
  • Weight loss and anorexia can be present.
  • In more severe cases fulminant amoebic colitis
    develops. Liver involvement is more common in
    these cases, along with paralytic ileus, toxic
    megacolon and mucosal sloughing. Over 75 of
    patients with fulminant colitis develop
    intestinal perforation.
  • Local inflammatory masses, amoebomas, may cause
    obstructive symptoms.
  • Hepatic
  • More common in men
  • Liver abscess pan present in conjunction with
    bowel symptoms (10 of cases), or in isolation.
  • Sudden onset of upper abdominal pain with fever.
    Pain may radiate to right shoulder or be
    exacerbated by repiratory movements.
  • Hepatic tenderness may be present. Jaundice is
    unusual.
  • Complicated liver abscess may develop if abscess
    ruptures into the peritoneal, pericardial or
    pleural cavity. Morbidity and mortality is high.
  • Rarely, trophozoites may also invade the
    respiratory tract, brain and GU tract

Presentation
Diagnosis
Treatment and Management
Vaccine Development 1
Vaccine Development 2
Vaccine Development 3
Self Assessment
17
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Diagnosis
  • Clinical history is important. In low resource
    settings this may be the means of diagnosis. A
    good travel history is important as disease may
    develop years after a visit to an endemic area.
  • Demonstration of E. histolytica in stool by
    microscopy (old), or ELISA assay for antigen
    detection. Trophozoites only survive for short
    periods of time, therefore, fresh stool samples
    should be used
  • Colonoscopy to confirm colitis and tissue biopsy
    for amoeba
  • Liver abscess space occupying lesion on CT/USS
    with positive amoebic serology

Presentation
Diagnosis
Treatment and Management
Vaccine Development 1
Vaccine Development 2
Vaccine Development 3
Self Assessment
18
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Treatment and Management
  • Amoebiasis, in particular with liver
    involvement, can be fatal if not treated.
    Chemotherapy can effectively cure ameobiasis.
  • Nitroimidazole (e.g.metronidazole) is used to
    treat the invasive pathogens 800mg t.d.s for 10
    days.
  • This is followed by a luminal agent
    (e.g.diloxanide furoate) to eliminate
    colonisation 500mg t.d.s for 10 days. This is
    also suitable for asymptomatic individuals.
  • Complicated liver abscesses should be drained
    surgically.
  • Prevention
  • Boiling water for at least ten minutes kills
    amoebic cysts effectively. Chlorine and iodine
    tablets are not thought to be 100 effective.

Presentation
Diagnosis
Treatment and Management
Vaccine Development 1
Vaccine Development 2
Vaccine Development 3
Self Assessment
19
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Vaccine Development 1
  • Amoebiasis incidence could be vastly reduced with
    simple sanitation and hygiene measures. However,
    given the current political and economic climate,
    this seems unlikely in the near future.
    Furthermore, with developing drug resistance in
    E. histolytica, vaccine development could be
    effective.
  • Why vaccinate?
  • Could prevent development of amoebic disease and
    associated sequelae.
  • Humans only host for E. histolytica, therefore
    eradication vaccine would eliminate E.
    histolytica from the carrier pool.
  • Which target?
  • A number of potential targets have been
    identified including cysteine proteases, LPGs and
    peroxiredoxins. The two most promising antigens
    identified are Serine-Rich E. histolytica Protein
    (SREHP) and Galactose/N-acetylgalactosamine
    lectin (Gal-lectin). Here the potential
    Gal-lectin vaccine will be described

Presentation
Diagnosis
Treatment and Management
Vaccine Development 1
Vaccine Development 2
Vaccine Development 3
Self Assessment
20
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Vaccine Development 2
  • Gal lectin and the immune response
  • Gal-lectin is a 260kDa complex protein which
    consists of disulphide linked light (35 kDa) and
    heavy subunits (170kDa). The heavy chain is
    cysteine rich and is thought to be a target for
    immune responses, inducing a Th1 cytokine cell
    mediated immune response
  • Macrophages induced by cytokines
    interferon(INF)-? have amoebocytic activity, as
    do T-cells exposed to INF-? exposed or TNF.
  • Trophozoite killing by macrophages is done via
    nitric oxide (NO). Gal-lectin can directly
    activate macrophages to release NO and induce
    mRNA transcription of Th1 cytokines, thereby
    enhancing the cell mediated immune response.
  • Monoclonal antibodies (MAbs), antiserum and IgA
    secreted from the gut mucosa against the
    Gal-Lectin antigen, have the ability to inhibit
    E. histolytica adherence to colonic mucosa in
    vitro.

Presentation
Diagnosis
Treatment and Management
Vaccine Development 1
Vaccine Development 2
Vaccine Development 3
Self Assessment
21
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Vaccine Development 3
  • Both Gal-lectin classical and DNA based vaccines
    have been tested in murine models.
  • Gal-lectin DNA vaccine
  • DNA of heavy gal-lec subunit used as vaccine
    (see Fig-5)4
  • Induced Th1 mediated anti-body specific response
    greater than control (nothing), however response
    was small. Vaccine moderately inhibited
    trophozoite adherence in vitro via anti-body
    action.

Protection conferred from purified and
recombinant vaccines
Presentation
Gal-lectin classical vaccine Purified (lectin)
and recombinant gal-letin (LecA) have been
trialled, showing good efficacy in preventing E.
histolytica pathogenesis. Immunisation were
intra-nasal and intra-peritoneal in order to
stimulate the gastrointestinal immunity.
Diagnosis
Protection
Treatment and Management
Vaccine Development 1
Vaccine Development 2
Production of DNA gal-lectin DNA vaccine in
murine model.
Vaccine Development 3
170
35
Self Assessment
Gene coding for portion of heavy gal-lec subunit
isolated
Transfected into plasmid
Muscle cells take up and incorporate gal-lec
sequence in DNA
Plasmid injected intra-muscularly
Protein expressed and immune response induced
22
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Questions
  • What are the symptoms of gastrointestinal
    amoebiasis?
  • What are the symptoms of hepatic amoebiasis?
  • Why is a good travel history important in
    diagnosis of amoebiasis?
  • What investigations can be performed to confirm a
    diagnosis?
  • Name two drugs and dosage regimes that can be
    used to treat amoebiasis.
  • Is the following statement true or false?
  • chlorine and iodine can be used to decontaminate
    water of E.histolytica with 100 effectiveness
  • 7) Does Gal-lectin induce a Th1 or Th2 cell
    mediated immune response?

Presentation
Diagnosis
Treatment and Management
Vaccine Development 1
Vaccine Development 2
Vaccine Development 3
Reveal Answer
Self Assessment
23
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Answers
  • What are the symptoms of gastrointestinal
    amoebiasis?
  • Gradual onset (weeks) of bloody diarrhoea,
    abdominal pain and tenderness, fever present in
    lt40 of patients, weight loss and anorexia,
    amoebomas, may cause obstructive symptoms.
  • What are the symptoms of hepatic amoebiasis?
  • Sudden onset of upper abdominal pain with fever.
    Pain may radiate to right shoulder or be
    exacerbated by repiratory movements.
  • Hepatic tenderness may be present. Jaundice is
    unusual
  • 3) Why is a good travel history important
    in diagnosis of amoebiasis?
  • A good travel history is vital to ascertain
    whether a patient has visited an endemic area.
    The disease may develop over a year after travel.
  • What investigations can be performed to confirm a
    diagnosis?
  • Demonstration of E. histolytica in stool by
    microscopy (old), or ELISA assay for antigen
    detection. Colonoscopy may be performed to check
    for colitis and biopsy. Check for liver abscess
    with USS or CT.
  • Name two drugs and dosage regimes that can be
    used to treat amoebiasis.
  • Nitroimidazole (e.g.metronidazole) 800mg t.d.s
    for 10 days. This is followed by a luminal agent
    (e.g.diloxanide furoate) 500mg t.d.s for 10 days.
  • 6) Is the following statement true or false?
  • chlorine and iodine can be used to decontaminate
    water of E.histolytica with 100 effectiveness
  • Boiling is the most effective methos for water
    decontamination
  • Does Gal-lectin induce a Th1 or Th2 cell mediated
    immune response?
  • Th1 cell mediated response

Presentation
Diagnosis
Treatment and Management
Vaccine Development 1
Vaccine Development 2
Vaccine Development 3
Self Assessment
24
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
Summary
  • Amoebiasis is a major global cause of mortality
    and morbidity, due to dysentery. The causative
    organism, E. histolytica.
  • E. histolytica has a biphasic life cycle and
    exists as an infective cyst and pathological
    trophozoite.
  • The disease is spread via contaminated food and
    water, usually due to poor sanitation.
  • The disease is found in tropical and sub-tropical
    parts of the world.
  • Every year, 40,000-100,000 people die from
    amoebiasis
  • Certain genetic traits pre-dispose to certain
    pathologies.
  • Patients usually present with abdominal pain,
    bloody stools and fever. Hepatic symptoms are
    more acute with upper abdominal pain and
    radiation to the right shoulder.
  • Treatment is with Nitroimidazole
    (e.g.metronidazole) and a luminal agent. Spread
    can be prevented by boiling water.
  • A potential gal-lectin vaccine is currently in
    development. Good results have been yielded with
    native gal-lectin vaccines, and moderate results
    with a DNA based vaccine. Immunity appears to be
    mainly via a Th1 cell medicated response and
    secretory IgA

Summary
References
25
cvcv
cvcv
cvcv
cvcv
cvcv
Introduction
Disease biology
Epidemiology
Clinical
Summary
References and further reading
  • Gaucher D., Chadee K. (2003). Prospect for an
    Entamoeba histolytica Gal-lectin-based vaccine.
    Parasite Immunology. 25, 5558 (review)
  • Gaucher D., Chadee K. (2002). Construction and
    immunogenicity of a codon-optimized Entamoeba
    histolytica Gal-lectin-based DNA vaccine.
    Vaccine. 20, 3244-3253
  • Houpt E., Barroso L., Lockhart L., Wright R.,
    Cramer C., Lyerly D., Petri W.A. (2003)
    Prevention of intestinal amebiasis by vaccination
    with the Entamoeba histolytica Gal/GalNac lectin.
    Vaccine. 22, 611617
  • Kelly P, Farthing M (2005) Protozoal
    gastrointestinal infections Medicine 33 4 ,
    81-83.
  • Stanley S.L. (2003) Amoebiasis. The lancet.
    361,1025-1034 (review)

Summary
References
Write a Comment
User Comments (0)
About PowerShow.com